Cargando…
A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients
BACKGROUND: Patients with prostate cancer (PC) may be ready to make trade-offs between their quantity and their quality of life. For instance, elderly patients may prefer the absence of treatment if it is associated with a low-risk of disease progression, compared to treatments aiming at preventing...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836440/ https://www.ncbi.nlm.nih.gov/pubmed/29506537 http://dx.doi.org/10.1186/s12955-018-0870-6 |
_version_ | 1783303968564183040 |
---|---|
author | Foucher, Yohann Lorent, Marine Tessier, Philippe Supiot, Stéphane Sébille, Véronique Dantan, Etienne |
author_facet | Foucher, Yohann Lorent, Marine Tessier, Philippe Supiot, Stéphane Sébille, Véronique Dantan, Etienne |
author_sort | Foucher, Yohann |
collection | PubMed |
description | BACKGROUND: Patients with prostate cancer (PC) may be ready to make trade-offs between their quantity and their quality of life. For instance, elderly patients may prefer the absence of treatment if it is associated with a low-risk of disease progression, compared to treatments aiming at preventing disease progression but with a substantial deterioration of their Health-Related Quality of Life (HRQoL). Therefore, it seems relevant to compare the treatments by considering both survival and HRQoL. In this mini-review, the aim was to question whether the potential trade-offs between survival and HRQoL are considered in high impact factor journals. METHODS: The study was conducted from the PubMed database for recent papers published between May 01, 2013, and May 01, 2015. We also restricted our search to nine medical journals with 2013 impact factor > 15. RESULTS: Among the 30 selected studies, only six collected individual HRQoL as a secondary endpoint by using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire. In four studies, the time to HRQoL change was analyzed, but its definitions varied. In two studies, the mean changes in HRQoL between the baseline and the 12- or 16-week follow-up were analyzed. None of the six studies reported in a single endpoint both the quantity and the quality of life. CONCLUSIONS: Our mini-review, which only focused on recent publications in journals with high-impact, suggests moving PC clinical research towards patient-centered outcomes-based studies. This may help physicians to propose the most appropriate treatment on behalf of patients. We recommend the use of indicators such as Quality-Adjusted Life-Years (QALYs) as principal endpoint in future clinical trials. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12955-018-0870-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5836440 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-58364402018-03-07 A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients Foucher, Yohann Lorent, Marine Tessier, Philippe Supiot, Stéphane Sébille, Véronique Dantan, Etienne Health Qual Life Outcomes Review BACKGROUND: Patients with prostate cancer (PC) may be ready to make trade-offs between their quantity and their quality of life. For instance, elderly patients may prefer the absence of treatment if it is associated with a low-risk of disease progression, compared to treatments aiming at preventing disease progression but with a substantial deterioration of their Health-Related Quality of Life (HRQoL). Therefore, it seems relevant to compare the treatments by considering both survival and HRQoL. In this mini-review, the aim was to question whether the potential trade-offs between survival and HRQoL are considered in high impact factor journals. METHODS: The study was conducted from the PubMed database for recent papers published between May 01, 2013, and May 01, 2015. We also restricted our search to nine medical journals with 2013 impact factor > 15. RESULTS: Among the 30 selected studies, only six collected individual HRQoL as a secondary endpoint by using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire. In four studies, the time to HRQoL change was analyzed, but its definitions varied. In two studies, the mean changes in HRQoL between the baseline and the 12- or 16-week follow-up were analyzed. None of the six studies reported in a single endpoint both the quantity and the quality of life. CONCLUSIONS: Our mini-review, which only focused on recent publications in journals with high-impact, suggests moving PC clinical research towards patient-centered outcomes-based studies. This may help physicians to propose the most appropriate treatment on behalf of patients. We recommend the use of indicators such as Quality-Adjusted Life-Years (QALYs) as principal endpoint in future clinical trials. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12955-018-0870-6) contains supplementary material, which is available to authorized users. BioMed Central 2018-03-05 /pmc/articles/PMC5836440/ /pubmed/29506537 http://dx.doi.org/10.1186/s12955-018-0870-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Foucher, Yohann Lorent, Marine Tessier, Philippe Supiot, Stéphane Sébille, Véronique Dantan, Etienne A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients |
title | A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients |
title_full | A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients |
title_fullStr | A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients |
title_full_unstemmed | A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients |
title_short | A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients |
title_sort | mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836440/ https://www.ncbi.nlm.nih.gov/pubmed/29506537 http://dx.doi.org/10.1186/s12955-018-0870-6 |
work_keys_str_mv | AT foucheryohann aminireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients AT lorentmarine aminireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients AT tessierphilippe aminireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients AT supiotstephane aminireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients AT sebilleveronique aminireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients AT dantanetienne aminireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients AT foucheryohann minireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients AT lorentmarine minireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients AT tessierphilippe minireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients AT supiotstephane minireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients AT sebilleveronique minireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients AT dantanetienne minireviewofqualityoflifeasanoutcomeinprostatecancertrialspatientcenteredapproachesareneededtoproposeappropriatetreatmentsonbehalfofpatients |